Start date: 01/10/2024
End date: 30/09/2025
Project Code: A4348_16386
Acronym: Enfermedad priónica humana
Since the endogenous prion protein plays a central role in the pathogenesis of prion diseases, gene therapy aimed at reducing the expression levels of this protein using CRISPR-Cas technology could represent a promising therapeutic strategy for these diseases and, potentially, for other neurodegenerative diseases such as Alzheimer's and Parkinson's, with similar pathogenic mechanisms.
